Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
Scienture Holdings (NASDAQ: SCNX) has announced a strategic financial move following the FDA approval of Arbli™, their novel liquid losartan formulation. The company has drawn from its Equity Line of Credit (ELOC) to support Arbli's commercial launch while simultaneously suspending further ELOC draws for either 30 trading days or until the stock reaches $10 per share.
Arbli™, the first FDA-approved ready-to-use oral liquid losartan in the U.S. market, is indicated for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients. The commercial launch is expected in Q3 2025.
Scienture Holdings (NASDAQ: SCNX) ha annunciato una mossa finanziaria strategica dopo l'approvazione da parte della FDA di Arbli™, la loro nuova formulazione liquida di losartan. L'azienda ha attinto dalla sua Linea di Credito Azionaria (ELOC) per supportare il lancio commerciale di Arbli, sospendendo nel contempo ulteriori prelievi di ELOC per 30 giorni di trading o fino a quando il prezzo delle azioni non raggiunge i 10 dollari per azione.
Arbli™, il primo losartan liquido orale pronto all'uso approvato dalla FDA nel mercato statunitense, è indicato per il trattamento dell'ipertensione in pazienti oltre i 6 anni, riducendo il rischio di ictus nei pazienti ipertesi con ipertrofia ventricolare sinistra e trattando la nefropatia diabetica in alcuni pazienti con diabete di tipo 2. Il lancio commerciale è previsto per il terzo trimestre del 2025.
Scienture Holdings (NASDAQ: SCNX) ha anunciado un movimiento financiero estratégico tras la aprobación de la FDA de Arbli™, su novedosa formulación líquida de losartán. La empresa ha utilizado su Línea de Crédito de Capital (ELOC) para apoyar el lanzamiento comercial de Arbli, mientras suspende simultáneamente más retiros de ELOC durante 30 días de negociación o hasta que la acción alcance los 10 dólares por acción.
Arbli™, el primer losartán líquido oral listo para usar aprobado por la FDA en el mercado estadounidense, está indicado para el tratamiento de la hipertensión en pacientes mayores de 6 años, reduciendo el riesgo de accidente cerebrovascular en pacientes hipertensos con hipertrofia ventricular izquierda y tratando la nefropatía diabética en ciertos pacientes con diabetes tipo 2. Se espera que el lanzamiento comercial tenga lugar en el tercer trimestre de 2025.
Scienture Holdings (NASDAQ: SCNX)는 Arbli™의 FDA 승인을 계기로 전략적 재정 조치를 발표했습니다. Arbli는 그들의 새로운 액상 로사르탄 제형입니다. 회사는 Arbli의 상업적 출시를 지원하기 위해 자본 신용 라인(ELOC)에서 자금을 인출했으며, 동시에 ELOC의 추가 인출을 30 거래일 동안 또는 주가가 주당 10달러에 도달할 때까지 중단합니다.
Arbli™는 미국 시장에서 FDA 승인을 받은 최초의 즉시 사용 가능한 경구 액상 로사르탄으로, 6세 이상의 환자에서 고혈압 치료, 좌심실 비대 환자의 뇌졸중 위험 감소, 그리고 특정 제2형 당뇨병 환자의 당뇨병성 신병증 치료에 적합합니다. 상업적 출시는 2025년 3분기로 예상됩니다.
Scienture Holdings (NASDAQ: SCNX) a annoncé un mouvement financier stratégique suite à l'approbation par la FDA d'Arbli™, leur nouvelle formulation liquide de losartan. L'entreprise a puisé dans sa Ligne de Crédit d'Équité (ELOC) pour soutenir le lancement commercial d'Arbli, tout en suspendant simultanément d'autres retraits d'ELOC pendant 30 jours de bourse ou jusqu'à ce que l'action atteigne 10 dollars par action.
Arbli™, le premier losartan liquide oral prêt à l'emploi approuvé par la FDA sur le marché américain, est indiqué pour le traitement de l'hypertension chez les patients de plus de 6 ans, réduisant le risque d'accident vasculaire cérébral chez les patients hypertendus avec hypertrophie ventriculaire gauche, et traitant la néphropathie diabétique chez certains patients atteints de diabète de type 2. Le lancement commercial est prévu pour le troisième trimestre 2025.
Scienture Holdings (NASDAQ: SCNX) hat einen strategischen finanziellen Schritt angekündigt, nachdem die FDA Arbli™, ihre neuartige flüssige Losartan-Formulierung, genehmigt hat. Das Unternehmen hat aus seiner Eigenkapitalkreditlinie (ELOC) Mittel entnommen, um den kommerziellen Start von Arbli zu unterstützen, während gleichzeitig weitere ELOC-Ziehungen für 30 Handelstage oder bis die Aktie 10 Dollar pro Aktie erreicht, ausgesetzt werden.
Arbli™, das erste von der FDA genehmigte gebrauchsfertige orale flüssige Losartan im US-Markt, ist zur Behandlung von Bluthochdruck bei Patienten über 6 Jahren angezeigt, reduziert das Schlaganfallrisiko bei hypertonen Patienten mit linksventrikulärer Hypertrophie und behandelt diabetische Nephropathie bei bestimmten Typ-2-Diabetikern. Der kommerzielle Start wird für das dritte Quartal 2025 erwartet.
- FDA approval received for Arbli™, first-of-its-kind liquid losartan product
- Commercial launch planned for Q3 2025
- Secured immediate capital through ELOC for product launch
- Additional dilution through ELOC draw
- Current share price below $10, indicating potential market concerns
Insights
Scienture Holdings has achieved a significant regulatory milestone with FDA approval of Arbli™, the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market. This approval represents substantial de-risking of the company's lead asset and creates a potential commercial opportunity in the antihypertensive market.
The company's decision to simultaneously draw on its Equity Line of Credit (ELOC) while temporarily suspending further draws reveals important financial dynamics. The immediate capital raise suggests insufficient cash reserves to fund commercialization efforts, a common challenge for micro-cap pharmaceutical companies. However, the self-imposed 30-day restriction on additional ELOC access (or until reaching
The Q3 2025 launch timeline for Arbli™ means revenue generation remains months away, explaining the current capital needs. With multiple approved indications including hypertension treatment, stroke risk reduction, and diabetic nephropathy management, Arbli™ targets diverse patient populations who may benefit from a liquid formulation (typically pediatric patients, elderly, and those with swallowing difficulties).
The stark contrast between Scienture's micro-cap status (
TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Suspension, while simultaneously announcing a temporary suspension of further ELOC draws for the next 30 trading days or until the company's stock reaches
The strategic financial decision comes on the heels of today's announcement that the U.S. Food and Drug Administration (FDA) has approved Scienture's New Drug Application (NDA) for Arbli™, the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market. The draw will provide immediate capital to support pre-launch activities for this novel antihypertensive medication.
"Following the momentous FDA approval of Arbli™ today, we have strategically accessed our Equity Line of Credit to ensure adequate capitalization for our commercial launch preparations," said Suren Ajjarapu, Chairman of the Board of Scienture Holdings, Inc. "Simultaneously, we believe it is in our shareholders' best interest to temporarily pause further draws from the ELOC as we navigate this exciting period in our company's growth trajectory."
The company has committed to refraining from additional draws on the ELOC for either 30 trading days or until its share price reaches
"With the FDA approval of Arbli™, we have reached a transformative milestone that positions us to address significant unmet needs for patients requiring a liquid formulation of losartan," said Narasimhan Mani, President of Scienture, LLC, a wholly owned subsidiary of Scienture Holdings. "This strategic financial approach balances our capital requirements for launching Arbli™ with our commitment to shareholder value."
The company expects to commercially launch Arbli™ and make it available to patients in the U.S. in Q3 2025. Arbli™ is indicated for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy, and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes.
About Arbli™
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. It comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 18 months from the date of manufacture when stored at room temperature.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
When will Scienture Holdings (SCNX) launch Arbli liquid losartan commercially?
What are the approved indications for Scienture's (SCNX) Arbli medication?
What conditions must be met for Scienture Holdings (SCNX) to resume ELOC draws?
What makes Scienture's (SCNX) Arbli unique in the U.S. market?
